Trial NCT04677660
Publication Masuda T, Vaccine, 2022
Primary outcome on the report: 1) solicited AEs through 7 days after each vaccination; 2) unsolicited AEs through 28 days after each vaccination; 3) MAAEs, SAEs, AEs leading to discontinuation of vaccination and AEs leading to participant withdrawal from the trial through day 57; 4) proportion of participants with SARS-CoV-2 infection through day 57; 5) serum bAb levels against SARS-CoV-2 on day 57

Note: The risk of bias by domain corresponds to the highest risk of bias among outcomes by domain.
The overall risk of bias corresponds to the overall highest risk of bias assessed among outcomes.